The PCI technology can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules (such as proteins and nucleic acids), vaccine antigens, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.

Macromolecules are widely acknowledged to have a large potential as therapeutic agents, and numerous clinical trials with gene, protein and oligonucleotide therapy are underway. The therapeutic potential of such compounds is challenged by the obstacles of intracellular delivery, and many studies have been hampered by the lack of technologies for efficient delivery of the therapeutic molecules to the target cells.